Vera Therapeutics (NASDAQ:VERA) Shares Up 5% – Here’s Why

Vera Therapeutics, Inc. (NASDAQ:VERA)’s share price was up 5% during trading on Tuesday . The company traded as high as $42.72 and last traded at $42.1470. Approximately 404,335 shares were traded during mid-day trading, a decline of 68% from the average session volume of 1,266,493 shares. The stock had previously closed at $40.13.

Analyst Ratings Changes

A number of brokerages have recently issued reports on VERA. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. The Goldman Sachs Group restated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Finally, Evercore set a $91.00 target price on shares of Vera Therapeutics in a research report on Friday, May 15th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average target price of $78.00.

Vera Therapeutics Stock Up 6.7%

The business has a fifty day simple moving average of $36.19 and a 200 day simple moving average of $41.24. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -7.75 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the previous year, the business earned ($0.81) earnings per share. As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. This trade represents a 8.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 59,951 shares of company stock valued at $2,392,387. Company insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC boosted its position in Vera Therapeutics by 26.7% during the first quarter. Janus Henderson Group PLC now owns 17,658 shares of the company’s stock worth $710,000 after acquiring an additional 3,723 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in Vera Therapeutics by 8.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock worth $645,000 after purchasing an additional 1,300 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Vera Therapeutics by 31.5% during the 1st quarter. California State Teachers Retirement System now owns 49,737 shares of the company’s stock worth $2,001,000 after purchasing an additional 11,907 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Vera Therapeutics by 190.6% during the 1st quarter. Royal Bank of Canada now owns 19,987 shares of the company’s stock worth $804,000 after purchasing an additional 13,108 shares during the last quarter. Finally, Quantinno Capital Management LP grew its position in shares of Vera Therapeutics by 72.6% in the first quarter. Quantinno Capital Management LP now owns 25,639 shares of the company’s stock valued at $1,031,000 after purchasing an additional 10,784 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.